Meeting News
Meeting News
Advertisement
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Read More
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Patrick DalyMyeloma | December 20, 2023
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Advertisement
Patrick DalyMyeloma | December 20, 2023
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Patrick DalyMyeloma | December 20, 2023
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
Leah SherwoodMeeting News | December 18, 2023
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Leah SherwoodMeeting News | December 18, 2023
Researchers said there was a need for potentially more effective one-time-only treatment options.
Hans Lee, MDMyeloma | December 19, 2023
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
Patrick DalyIndolent B-Cell Lymphoma | February 16, 2024
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Noopur Raje, MDMyeloma | December 18, 2023
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | December 15, 2023
Patients with lenalidomide-refractory MM had significant improvements in health-related QoL and symptoms after cilta-cel.
Patrick DalyMyeloma | December 13, 2023
Cilta-cel was significantly more cost-effective versus DPd or PVd regimens in relapsed or refractory multiple myeloma.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | February 2, 2024
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
Melissa BadamoMantle Cell Lymphoma | December 13, 2023
The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples.
Jeffrey Matous, MDMyeloma | December 13, 2023
Jeffrey Matous, MD, discusses data from the phase Ib MonumenTAL-2 study on talquetamab plus pomalidomide in multiple myeloma.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Advertisement
Advertisement
Editorial Board